Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Audio recording of meeting between GSK and Dr Nissen to discuss Avandia
Audio recording of meeting between GSK and Dr Nissen to discuss Avandia
-
GlaxoSmithKline and Genmab announce start of ofatumumab Phase III combination study in non-Hodgkin’s lymphoma
GSK and GEN announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin’s lymphoma (B-NHL).
-
GSK announces succession plan for Chief Financial Officer
GSK announces that Julian Heslop is to retire as Chief Financial Officer and Executive Director of the company at the end of March 2011.
-
Galapagos reaches agreement to acquire GlaxoSmithKline research centre in Zagreb, Croatia
R&D operations in Zagreb fulfil Galapagos; growing R&D capacity requirements
-
GSK signs agreement with Lonza to secure capacity and expertise in biological manufacturing to support ongoing development of GSK’s biopharmaceuticals portfolio
GSK and Lonza today announced that they have entered into a new agreement under which Lonza will support the ongoing development of GSK.
-
BBC Panorama – 6 September 2010
Patient safety is our first priority. We strongly refute any allegation that our actions have put patients at risk.
-
GlaxoSmithKline pre-broadcast statement: BBC Panorama, 6 September 2010
GSK today issued the statement in anticipation of the BBC programme, A risk worth taking which is scheduled to be aired this evening.
-
GlaxoSmithKline responds to British Medical Journal article regarding Avandia® (rosiglitazone)
GSK continues to work in the best interest of diabetes patients who face this chronic and serious disease.
-
Reports of narcolepsy in Europe following vaccination with Pandemrix™
GSK became aware of cases of narcolepsy following vaccination with the adjuvanted H1N1 pandemic vaccine Pandemrix.
-
GSK and Valeant announce new U.S. FDA PDUFA goal date for ezogabine
GSK and VRX announced today FDA has extended the PDUFA goal date for ezogabine* to 30 Nov 2010, the original goal date was 30 August 2010.
-
GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles
GSK confirmed that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine.
-
GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus
GSK and Human Genome Sciences, Inc. today announced that the FDA has granted a priority review designation to Benlysta.
-
GSK and Genmab announce topline results from the concluded pivotal trial of Arzerra (ofatumumab) in fludarabine and alemtuzumab refractory chronic lymphocytic leukemia
GSK and GEN announced today top line results from the concluded pivotal trial.
-
Image of new antibiotic in action opens up new opportunities to combat antibacterial resistance
Pictures have been published showing how a type of experimental antibiotic can kill bacteria already resistant to existing treatments.
-
GSK exercises option on Anacor’s novel antibiotic for the treatment of gram-negative infections
GSK and Anacor Pharmaceuticals today announced that GSK has exercised its option to obtain an exclusive licence to develop.
-
GSK receives CHMP positive opinion for a new indication for Arixtra
GSK today announced that CHMP has issued a positive opinion for Arixtra (fondaparinux),an anti-clotting drug (antithrombotic).
-
GlaxoSmithKline statement in response to FDA announcement on TIDE trial
GSK confirmed that it will suspend enrollment of new patients in TIDE clinical trial at the request of FDA.
-
GSK announces Q2 results for 2010
Q2 EPS before major restructuring* 2.6p (29.3p excluding pre-announced legal charge)
-
GlaxoSmithKline legal update
GSK today announces that it expects to record a legal charge for the second quarter of 2010 of £1.57billion ($2.36 billion).
-
GlaxoSmithKline statement in response to FDA Advisory Committees’ vote on safety of Avandia® (rosiglitazone)
GSK confirmed that a joint advisory committee to the FDA voted to allow Avandia to remain on the market.